Indocyanine green (ICG) is a Food and Drug Administration–approved near-infrared fluorescent dye, employed as an imaging agent for different clinical applications due to its attractive physicochemical properties, high sensitivity, and safety. However, free ICG suffers from some drawbacks, such as relatively short circulation half-life, concentration-dependent aggregation, and rapid clearance from the body, which would confine its feasible application in oncology. Here, we aim to discuss encapsulation of ICG within a nanoparticle formulation as a strategy to overcome some of its current limitations and to enlarge its possible applications in cancer diagnosis and treatment. Our purpose is to provide a short but exhaustive overview of clinical outcomes that these nanocomposites would provide, discussing opportunities, limitations, and possible impacts with regard to the main clinical needs in oncology.
Indocyanine Green Nanoparticles : Are They Compelling for Cancer Treatment? / M. Sevieri, F. Silva, A. Bonizzi, L. Sitia, M. Truffi, S. Mazzucchelli, F. Corsi. - In: FRONTIERS IN CHEMISTRY. - ISSN 2296-2646. - 8:(2020 Jul 16), pp. 535.1-535.9. [10.3389/fchem.2020.00535]
Indocyanine Green Nanoparticles : Are They Compelling for Cancer Treatment?
M. SevieriPrimo
;F. SilvaSecondo
;A. Bonizzi;L. Sitia;S. Mazzucchelli
Penultimo
;F. Corsi
Ultimo
2020
Abstract
Indocyanine green (ICG) is a Food and Drug Administration–approved near-infrared fluorescent dye, employed as an imaging agent for different clinical applications due to its attractive physicochemical properties, high sensitivity, and safety. However, free ICG suffers from some drawbacks, such as relatively short circulation half-life, concentration-dependent aggregation, and rapid clearance from the body, which would confine its feasible application in oncology. Here, we aim to discuss encapsulation of ICG within a nanoparticle formulation as a strategy to overcome some of its current limitations and to enlarge its possible applications in cancer diagnosis and treatment. Our purpose is to provide a short but exhaustive overview of clinical outcomes that these nanocomposites would provide, discussing opportunities, limitations, and possible impacts with regard to the main clinical needs in oncology.File | Dimensione | Formato | |
---|---|---|---|
fchem-08-00535.pdf
accesso aperto
Tipologia:
Publisher's version/PDF
Dimensione
624.07 kB
Formato
Adobe PDF
|
624.07 kB | Adobe PDF | Visualizza/Apri |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.